Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18721)	4/6/1998 9:21:00 PM
From: Machaon	Read Replies (3) \| Respond to of 32384

Henry, it looks like your analysis of the Tamoxifen news, was totally correct. I just got thru listening to the 30 minute CNN special about Breast Cancer and Tamoxifen. The subject of new, safer drugs, in the pipeline, was mentioned over and over, especially 2nd generation SERMs. They also mentioned Droloxifene, as one of the new SERMs that might be better than Tamoxifen, and without the side effects. The National Cancer Institute spokeswoman said that their next step is to test some of these new drugs. Overall, the broadcast was favorable towards LGND. I kept saying, "They're talking about LGND", over and over. Anyone else get the same reaction? I've got a full position in LGND, at current. I've got to avoid the temptation to get more shares. Regards, Bob